NCT06246279

Brief Summary

Adolescence period; It is a transition period of rapid growth, development and maturation in biochemical, physical, social and spiritual terms, which lasts from the beginning of puberty to young adulthood. Adolescence is a predictable developmental transition period for the individual. They also encounter unpredictable situations (such as childhood illnesses). One of these conditions is Type 1 Diabetes Mellitus, which is the most common metabolic endocrine system disease in adolescents. Type 1 diabetes is an important health/disease transition in the life of a child and adolescent. Therefore, this study aimed to determine the effect of the "Adaptation to Adolescence and Type 1 Diabetes Management Training Programme", prepared in line with Meleis's Transition Theory, on the adolescent's developmental transition adaptation, self-efficacy for diabetes management and glycemic control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2022

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

January 30, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 7, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2024

Completed
Last Updated

July 31, 2024

Status Verified

July 1, 2024

Enrollment Period

2.1 years

First QC Date

January 30, 2024

Last Update Submit

July 30, 2024

Conditions

Keywords

Type 1 DiabetesTransition TheoryDiabetes ManagementPediatric NurseRandomized Controlled Trial

Outcome Measures

Primary Outcomes (1)

  • Reynolds Adjustment Screening Inventory for Adolescents

    Reynolds Adjustment Screening Inventory has four subscales. These; emotional distress (10 items), antisocial behavior (8 items), positive self (6 items related to self-confidence and socialization) and anger control problems (8 items). The Cronbach alpha value of the scale is stated as 0.91. The lowest score of the scale is 32 and the highest score is 165.

    This scale was administered three times at beginning, 3rd and 6th months.

Secondary Outcomes (2)

  • Diabetes Management Self-Efficacy Scale in Adolescents with Type 1 Diabetes

    This scale was administered three times at beginning, 3rd and 6th months.

  • Glycemic Control - Hemoglobin A1C

    This scale was administered three times at beginning, 3rd and 6th months.

Study Arms (2)

Experimental group

EXPERIMENTAL

In addition to the institution's routine T1DM training, the "Adjustment to Adolescence and Transition to Type 1 Diabetes Education Program" prepared in line with Meleis's Transition Theory was applied to adolescents online via the Microsoft Teams Program.

Behavioral: Adaptation to Adolescence and Type 1 Diabetes Management Training Program

Control group

NO INTERVENTION

The institution's routinely planned diabetes education was given by the pediatric diabetes education nurse.

Interventions

The content of the Training Program was created by researchers based on Transition Theory, in line with high-level research results and international guides. Then, the necessary arrangements were made by taking the opinions of 10 experts (child health and disease nursing faculty member, child and adolescent mental health specialist, child endocrinologist, child development specialist, nutrition and dietetics specialist, sports training specialist). The content was finalized in line with the comments received.

Experimental group

Eligibility Criteria

Age12 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Having been diagnosed with type 1 diabetes in the last 6 months
  • HbA1c level \>7.5

You may not qualify if:

  • presence of a diagnosis of intellectual disability, autism spectrum disorder and psychotic disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Akdeniz Univercity

Antalya, 07100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Adolescent BehaviorDiabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

BehaviorDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Ceren Calik

    Akdeniz Univercity

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Master of Science, specialist nurse

Study Record Dates

First Submitted

January 30, 2024

First Posted

February 7, 2024

Study Start

April 1, 2022

Primary Completion

April 30, 2024

Study Completion

April 30, 2024

Last Updated

July 31, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Locations